Division of Roche
Latest From Ignyta Inc.
Former Ignyta executive Zachary Hornby wasn't wowed by immuno-oncology pitches when looking for his next cancer drug development company, but was intrigued by ecDNA research at UCSD, which also could generate a tumor agnostic approach.
Roche’s tumor-agnostic drug receives first approval globally in Japan following an expedited review, giving the Swiss group a lead over its rival in this market. But sales may be limited.
Lim, CEO of Ignyta when it was sold to Roche earlier this year, has moved on to the start-up Erasca with $42m in Series A venture cash to develop "precision oncology" drugs.
Roche’s investigational non-small cell lung cancer candidate entrectinib has shown to reduce tumors in people with ROS1-positive NSCLC, including those whose disease had spread to the central nervous system, differentiating it from potential competitors.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Senior Management
Jonathan E Lim, MD, Chmn. & CEO
Jacob Chacko, MD, CFO
Zachary Hornby, COO
William McCarthy, CBO
Pratik S Multani , MD, CMO
- Contact Info
Phone: (858) 255-5959
4545 Towne Centre Ct.
San Diego, CA 92121
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.